Diagnóstico de mieloma múltiple
Multiple myeloma is a malignant disease characterized by the abnormal proliferation of plasma cells, the prognosis of patients with this disease is highly variable, with a median survival of 2.5 to 3 years, the average age of their condition is around 65 years old. Only 12 percent and 3 percent of p...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Spanish |
| Published: |
2022
|
| Subjects: | |
| Online Access: | https://dialnet.unirioja.es/servlet/oaiart?codigo=8374650 |
| Source: | RECIMUNDO: Revista Científica de la Investigación y el Conocimiento, ISSN 2588-073X, Vol. 6, Nº. 2, 2022, pags. 133-142 |
| Tags: |
Add Tag
No Tags: Be the first to tag this record
|
| id |
dialnet-ar-18-ART0001522083
|
|---|---|
| record_format |
dialnet
|
| institution |
Dialnet
|
| collection |
Dialnet AR
|
| source |
RECIMUNDO: Revista Científica de la Investigación y el Conocimiento, ISSN 2588-073X, Vol. 6, Nº. 2, 2022, pags. 133-142
|
| language |
Spanish
|
| topic |
Mieloma
Radiaciones Biopsia Trasplante Sobrevida Myeloma Radiation Biopsy Transplantation Survival |
| spellingShingle |
Mieloma
Radiaciones Biopsia Trasplante Sobrevida Myeloma Radiation Biopsy Transplantation Survival Monroy Pesantez, Maria Fernanda Saracay Carrillo, Helen Eliana Domínguez Vacacela, Elio Darío Huang Carpio, Juan José Diagnóstico de mieloma múltiple |
| description |
Multiple myeloma is a malignant disease characterized by the abnormal proliferation of plasma cells, the prognosis of patients with this disease is highly variable, with a median survival of 2.5 to 3 years, the average age of their condition is around 65 years old. Only 12 percent and 3 percent of patients are under 50 and 40 years old, respectively. The methodology used for this research work is framed within a bibliographic review of documentary type, since we are going to deal with issues raised at a theoretical level such as Diagnosis of multiple myeloma. The technique for data collection is made up of electronic materials, the latter such as Google Scholar, PubMed, among others, relying on the use of descriptors in health sciences or MESH terminology. The information obtained here will be reviewed for further analysis. We can conclude within what was analyzed in the development of this research, that multiple myeloma is a chronic condition, and that despite the fact that there are different types of treatments, it is incurable, at least so far, despite the combination of different drugs and existing transplants, what these treatments do is prolong the life of patients, for a period so far no longer than 5 years in most cases and one of the predominant factors in the outcome of this disease it is age, since it affects people over 60 years of age associated with comorbidities that may worsen prognosis and survival, and risk factors associated so far with exposure to radiation and chemical substances, supported by international studies. As for the diagnosis, like the rest of the diseases, it has an initial physical assessment, followed by laboratory tests and images that confirm it.
|
| format |
Article
|
| author |
Monroy Pesantez, Maria Fernanda
Saracay Carrillo, Helen Eliana Domínguez Vacacela, Elio Darío Huang Carpio, Juan José |
| author_facet |
Monroy Pesantez, Maria Fernanda
Saracay Carrillo, Helen Eliana Domínguez Vacacela, Elio Darío Huang Carpio, Juan José |
| author_sort |
Monroy Pesantez, Maria Fernanda
|
| title |
Diagnóstico de mieloma múltiple
|
| title_short |
Diagnóstico de mieloma múltiple
|
| title_full |
Diagnóstico de mieloma múltiple
|
| title_fullStr |
Diagnóstico de mieloma múltiple
|
| title_full_unstemmed |
Diagnóstico de mieloma múltiple
|
| title_sort |
diagnóstico de mieloma múltiple
|
| publishDate |
2022
|
| url |
https://dialnet.unirioja.es/servlet/oaiart?codigo=8374650
|
| _version_ |
1767464017868095488
|
| spelling |
dialnet-ar-18-ART00015220832023-05-30Diagnóstico de mieloma múltipleMonroy Pesantez, Maria FernandaSaracay Carrillo, Helen ElianaDomínguez Vacacela, Elio DaríoHuang Carpio, Juan JoséMielomaRadiacionesBiopsiaTrasplanteSobrevidaMyelomaRadiationBiopsyTransplantationSurvivalMultiple myeloma is a malignant disease characterized by the abnormal proliferation of plasma cells, the prognosis of patients with this disease is highly variable, with a median survival of 2.5 to 3 years, the average age of their condition is around 65 years old. Only 12 percent and 3 percent of patients are under 50 and 40 years old, respectively. The methodology used for this research work is framed within a bibliographic review of documentary type, since we are going to deal with issues raised at a theoretical level such as Diagnosis of multiple myeloma. The technique for data collection is made up of electronic materials, the latter such as Google Scholar, PubMed, among others, relying on the use of descriptors in health sciences or MESH terminology. The information obtained here will be reviewed for further analysis. We can conclude within what was analyzed in the development of this research, that multiple myeloma is a chronic condition, and that despite the fact that there are different types of treatments, it is incurable, at least so far, despite the combination of different drugs and existing transplants, what these treatments do is prolong the life of patients, for a period so far no longer than 5 years in most cases and one of the predominant factors in the outcome of this disease it is age, since it affects people over 60 years of age associated with comorbidities that may worsen prognosis and survival, and risk factors associated so far with exposure to radiation and chemical substances, supported by international studies. As for the diagnosis, like the rest of the diseases, it has an initial physical assessment, followed by laboratory tests and images that confirm it.El mieloma múltiple es una enfermedad maligna caracterizada por la proliferación anormal de células plasmáticas, el pronóstico de los pacientes con esta enfermedad es muy variable, con una mediana de sobrevida de 2,5 a 3 años, la media de edad de su padecimiento se sitúa alrededor de los 65 años. Únicamente el 12 por ciento y el 3 por ciento de los pacientes tienen menos de 50 y 40 años, respectivamente. La metodología utilizada para el presente trabajo de investigación, se enmarcada dentro de una revisión bibliográfica de tipo documental, ya que nos vamos a ocupar de temas planteados a nivel teórico como es Diagnóstico de mieloma múltiple. La técnica para la recolección de datos está constituida por materiales electrónicos, estos últimos como Google Académico, PubMed, entre otros, apoyándose para ello en el uso de descriptores en ciencias de la salud o terminología MESH. La información aquí obtenida será revisada para su posterior análisis. Podemos concluir dentro de lo analizado en el desarrollo de esta investigación, que el mieloma múltiple es una afección crónica, y que a pesar de que existen diferentes tipos de tratamientos, la misma es incurable, por lo menos hasta el momento, a pesar de la combinación de diferentes fármacos y los trasplantes existentes, estos tratamientos lo que hacen es prolongar la vida de los pacientes, por un lapso hasta ahora no mayor de 5 años en la mayoría de los casos y uno de los factores predominantes en el desenlace de esta enfermedad es la edad, ya que afecta a personas mayores de 60 años asociados a comorbilidades que se puedan presentar que empeoran el pronóstico y la sobrevida y factores de riesgo asociados hasta ahora a exposiciones a radiaciones y a sustancias químicas, sustentadas por estudios a nivel internacional. En cuanto al diagnóstico como el resto de enfermedades, tiene una valoración física inicial, seguida de exámenes de laboratorio y por imágenes que la confirman.2022text (article)application/pdfhttps://dialnet.unirioja.es/servlet/oaiart?codigo=8374650(Revista) ISSN 2588-073XRECIMUNDO: Revista Científica de la Investigación y el Conocimiento, ISSN 2588-073X, Vol. 6, Nº. 2, 2022, pags. 133-142spaLICENCIA DE USO: Los documentos a texto completo incluidos en Dialnet son de acceso libre y propiedad de sus autores y/o editores. Por tanto, cualquier acto de reproducción, distribución, comunicación pública y/o transformación total o parcial requiere el consentimiento expreso y escrito de aquéllos. Cualquier enlace al texto completo de estos documentos deberá hacerse a través de la URL oficial de éstos en Dialnet. Más información: https://dialnet.unirioja.es/info/derechosOAI | INTELLECTUAL PROPERTY RIGHTS STATEMENT: Full text documents hosted by Dialnet are protected by copyright and/or related rights. This digital object is accessible without charge, but its use is subject to the licensing conditions set by its authors or editors. Unless expressly stated otherwise in the licensing conditions, you are free to linking, browsing, printing and making a copy for your own personal purposes. All other acts of reproduction and communication to the public are subject to the licensing conditions expressed by editors and authors and require consent from them. Any link to this document should be made using its official URL in Dialnet. More info: https://dialnet.unirioja.es/info/derechosOAI
|